公开(公告)号：US20230277533A1

公开(公告)日：2023-09-07

申请号：US17904159

申请日：2021-02-12

申请人： KSQ Therapeutics, Inc.

发明人： Andrew Alistair WYLIE ,  Solomon Martin SHENKER ,  Pamela Jean SULLIVAN ,  Frank STEGMEIER ,  Anne Louise CADZOW ,  Hanlan LIU ,  Kerstin Wolf SINKEVICIUS

IPC分类号： A61K31/502 ,  A61K31/454 ,  A61K31/519 ,  A61K31/55 ,  A61K31/5025 ,  A61P35/00

CPC分类号： A61K31/502 ,  A61K31/454 ,  A61K31/519 ,  A61K31/55 ,  A61K31/5025 ,  A61P35/00

摘要： The present disclosure provides therapeutic combinations comprising (i) a ubiquitin-specific-processing protease 1 (USP1) inhibitor and (ii) a poly ADP-ribose polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid, or polymorph thereof, wherein the USP1 inhibitor comprises (I), (II), or (III), or pharmaceutically acceptable salts, hydrates, solvates, amorphous solids, or polymorphs thereof. The present disclosure is also directed to the use of the combinations to inhibit a USP1 and/or PARP protein and/or to treat a disorder responsive to the inhibition of USP1 and/or PARP proteins and USP1 and/or PARP activity. The combinations of the present disclosure are especially useful for treating cancer.

公开(公告)号：US20200347386A1

公开(公告)日：2020-11-05

申请号：US16781732

申请日：2020-02-04

申请人： KSQ Therapeutics, Inc.

发明人： Micah BENSON ,  Michael SCHLABACH ,  Gregory KRYUKOV ,  Anne Louise CADZOW ,  Isabelle Fleur LE MERCIER ,  Frank STEGMEIER

IPC分类号： C12N15/11 ,  C12N9/22 ,  C12N15/86 ,  A61K35/17 ,  A61K49/00 ,  C12N5/0783

摘要： The present disclosure provides methods and compositions related to the modification of immune effector cells to increase therapeutic efficacy. In some embodiments, immune effector cells modified to reduce expression of one or more endogenous target genes, or to reduce one or more functions of an endogenous protein to enhance effector functions of the immune cells are provided. In some embodiments, immune effector cells further modified by introduction of transgenes conferring antigen specificity, such as exogenous T cell receptors (TCRs) or chimeric antigen receptors (CARs) are provided. Methods of treating a cell proliferative disorder, such as a cancer, using the modified immune effector cells described herein are also provided.